These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 16554943)
1. Alzheimer disease: disease modifying trials; where are we? Where do we need to go? A reflective paper. Sampaio C J Nutr Health Aging; 2006; 10(2):113-5. PubMed ID: 16554943 [No Abstract] [Full Text] [Related]
2. Outcomes for disease modifying trials. Wilcok G J Nutr Health Aging; 2007; 11(4):318-9. PubMed ID: 17653489 [No Abstract] [Full Text] [Related]
3. Biomarkers in Alzheimer's disease. Lovestone S J Nutr Health Aging; 2006; 10(2):118-22. PubMed ID: 16554945 [No Abstract] [Full Text] [Related]
4. Recruitment of subjects into clinical trials for Alzheimer disease. Knebl JA; Patki D J Am Osteopath Assoc; 2010 Sep; 110(9 Suppl 8):S43-9. PubMed ID: 20926743 [TBL] [Abstract][Full Text] [Related]
5. Drug discovery and the prevention of Alzheimer's disease. Fillit H Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S26-8. PubMed ID: 18631996 [TBL] [Abstract][Full Text] [Related]
7. [The phenomenon of different study results. Were the research participants too old?]. Röhm W MMW Fortschr Med; 2009 Jan; 151(1-2):7. PubMed ID: 19227629 [No Abstract] [Full Text] [Related]
8. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Who may benefit from disease-modifying studies in Alzheimer's disease? Gauthier S; Poirier J Alzheimers Dement; 2009 Mar; 5(2):147-8. PubMed ID: 19328447 [No Abstract] [Full Text] [Related]
9. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Primary prevention of dementia in Alzheimer's disease: a perspective from prevention research in cardiovascular disease and stroke. Fillit H; Nash DT; Shineman D Alzheimers Dement; 2009 Mar; 5(2):149-53. PubMed ID: 19328448 [No Abstract] [Full Text] [Related]
10. Disease modifying trials in Alzheimer disease: methodological and statistical issues. Andrieu S; Rascol O; Lang T; Grandjean H; Vellas B J Nutr Health Aging; 2006; 10(2):116-7. PubMed ID: 16554944 [TBL] [Abstract][Full Text] [Related]
11. Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. Scheltens P; Barkhof F J Nutr Health Aging; 2006; 10(2):123-8; discussion 129-30. PubMed ID: 16554946 [TBL] [Abstract][Full Text] [Related]
12. Biomarkers for disease modification trials--the innovative medicines initiative and AddNeuroMed. Lovestone S; Francis P; Strandgaard K J Nutr Health Aging; 2007; 11(4):359-61. PubMed ID: 17653500 [No Abstract] [Full Text] [Related]
13. Current challenges for the successful treatment and prevention of Alzheimer's disease: treating the pathologies of the disease to change its clinical course. Schenk D Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S119-21. PubMed ID: 18631987 [TBL] [Abstract][Full Text] [Related]
14. What do people at risk for Alzheimer disease think about surrogate consent for research? Schenk DB; Gilman S Neurology; 2006 Jun; 66(11):1785-6. PubMed ID: 16769971 [No Abstract] [Full Text] [Related]
19. Commentary on "a roadmap for the prevention of dementia: the inaugural Leon Thal Symposium." An impending prevention clinical trial for Alzheimer's disease: roadmaps and realities. Roses AD Alzheimers Dement; 2008 May; 4(3):164-6. PubMed ID: 18631961 [No Abstract] [Full Text] [Related]
20. The intricacies of heart failure. Rasmusson KD; Hall JA; Renlund DG Nurs Manage; 2007 May; 38(5):33-40; quiz 40-1. PubMed ID: 17486012 [No Abstract] [Full Text] [Related] [Next] [New Search]